Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimazolam for sedation in digestive endoscopy
ChiCTR2200064794Phase 4Recruiting
- Sponsor
- Tianjin Nankai Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in obstructive jaundice (3 arms), sponsored by Tianjin Nankai Hospital. Primary endpoints: Safety and sedation success rate of remimazolam in gastroscopy and colonoscopy, Incidence of hypotension and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
remimazolam
03
Conditions
obstructive jaundice
Beyond the preview
Go deeper on ChiCTR2200064794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064794.